1. Home
  2. |Insights
  3. |Taking It to the Bank: FCA Case Dismissed Because Federal Reserve Banks Are Not the U.S. Government

Taking It to the Bank: FCA Case Dismissed Because Federal Reserve Banks Are Not the U.S. Government

Client Alert | 1 min read | 05.16.18

On remand from the U.S. Supreme Court and Second Circuit to reconsider its earlier dismissal of a long-running civil False Claims Act (FCA) lawsuit based upon implied and express certification theories undermined by the 2016 Escobar decision, the U.S. District Court for the Eastern District of New York concluded in United States ex rel. Bishop v. Wells Fargo & Co. that the lawsuit should be dismissed because no claims had been submitted to, or reimbursed by, the government. Relators claimed the defendants violated the FCA by engaging in “extensive accounting and control fraud” that allegedly distorted the financial condition of defendants in such a way as to make them eligible to borrow short-term funds from the Federal Reserve Banks’ (FRBs) Discount Window at the lower interest rate and to borrow longer-term funds from the FRBs’ Term Auction Facility, which they would not have been entitled to borrow without the alleged fraudulent distortions. The court concluded - as a matter of first impression – that FRBs do not act as the government or its agents under the FCA and that the government does not “provide funds to or reimburse FRBs for the conduct relevant here.”

Specifically, the court identified and considered a number of factors for determining whether a federally-established entity qualifies as the government for purposes of the FCA, and concluded FRBs were not because: (a) the statutory history and the language of the Federal Reserve Act placed FRBs outside of the government; (b) “each FRB is a private corporation, owned by private stockholders made up of national banks,” and “FRBs do not receive government appropriations to operate;” (c) FRB leadership is independent of the government and FRB employees are not government employees; and (d) FRBs function and operate independently from the Board of Governors of the Federal Reserve System and the government. 

Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...